Member Video Of The Week
Video from Water Mission.
From Our Blog
Vaccines Touch Down Across Africa: Now the Work Begins
By Emily Bancroft, President, VillageReach
I never thought I’d be so excited by pictures of boxes being unloaded from airplanes. When I saw the photos come streaming across social media this week, I breathed a deep sigh of relief. The pallets being wheeled onto the tarmac meant that COVID-19 vaccines had arrived in Mozambique, the Democratic Republic of the Congo (DRC), Côte d’Ivoire, Malawi and many other African countries. As government officials and partners began to unpack the containers, we all knew the hard work was just beginning.
Malawi officials receive COVAX delivery at Kamuza International Airport. | Photo Credit: Hope Ngwira
Over the last year, as the scientific community quickly mobilized to develop, test and produce multiple effective vaccines, the focus for VillageReach has been protecting health workers and communities against the virus. As an organization dedicated to the delivery of vaccines, medicines, supplies and information, COVID-19 vaccine delivery has been constantly on our minds. We participated in the Country Readiness and Delivery working group of the vaccine pillar of the Access to COVID Tools Accelerator (ACT-A) to help link global-level plans with country efforts.
Recent Blog Posts
- Agros: Tackling Poverty and Climate Change through Agriculture
- Tackling SDG10 Means Shifting Power and Profits
- “Years don’t wait for them”: 5 Things to Do Now to Protect Children’s Rights During Covid-19
- Responding to COVID-19 with Financial Inclusion Solutions
- Future of Fish Helps Peru’s Small-Scale Fisheries Acquire PPE to Stay Afloat in Pandemic
Organization Profile
How Seattle’s Fred Hutchinson Cancer Research Center Became a Global Leader in Testing COVID-19 Vaccines
By Joanne Lu
The global path of COVID-19. Image courtesy of Fred Hutch.
When COVID-19 first made landfall in the U.S. last year, it made its grand entrance in Snohomish County, Washington, and eventually turned Seattle into the country’s “coronavirus capital” for some months. So, in a way, it’s only fitting that the institution at the center of the vaccine development campaign to end the pandemic is based in Seattle, as well.
Goalmaker
New Head of PATH, Nikolaj Gilbert, Brings Flexibility and Partnership Prowess to Global Health
By Andie Long
Photo courtesy of PATH.
Nikolaj Gilbert joined PATH, a global public health organization headquartered in Seattle, in January of 2020 – just as the first cases of COVID-19 began appearing globally and shortly before the first U.S. cases were reported in Washington state. With little more than a year on the job, having immigrated to the United States from Denmark with his family and onboarded to PATH almost entirely virtually, the new CEO already has a strong vision for the future, one that challenges it to be an even better global partner.
PATH works locally, with national and sub-national health organizations around the world, as well as globally with partners like the World Health Organization, developing vaccines, devices, and tools that can reach people who would otherwise not have access. This expertise has been essential in light of the global pandemic, as many of the hardest hit communities navigate COVID-19 on top of other major health threats. Doing this well requires a strong set of institutional values that drive all of PATH’s work – and Gilbert is the right leader for the job.
Members News
PRESS RELEASE: Oxfam Reaction to Johnson & Johnson Vaccine Submission for FDA Approval
In response to Johnson & Johnson (JNJ)’s submission of their COVID-19 vaccine for emergency approval from the US Food & Drug Administration, Niko Lusiani, Senior Advisor with Oxfam America, made the following statement:
“Scientists have yet again delivered hope in the war against the coronavirus. As a single-dose and lower-cost vaccine, the JNJ vaccine could deliver the necessary boost the world needs to save lives and rebuild our economy.
“Now it’s time for executives and policy makers to deliver a people’s vaccine that is mass produced around the world to ensure access to the greatest number of people in the shortest amount of time. JNJ can only produce the vaccine for less than 13 percent of the global population by the end of the year.
Recent News Posts
- PRESS RELEASE: Adara Development appoints Madeline Vaughan as new CEO
- PRESS RELEASE: Sultan Latif has joined Save the Children as Director of the Humanitarian Climate Crisis Unit (HCCU)
- Statement from Global Washington Executive Director, Kristen Dailey, on the passing of Bill Gates Sr.
- PRESS RELEASE: COVID-19: Children From Poorest Households Had Greatest Financial and Education Loss, Highest Risk of Violence at Home
- PRESS RELEASE: Americares Responds to COVID-19 Surge in Peru
